Loading...
Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance
We examined an immediate, but short-lived, response to crizotinib, a drug with a new indication for ROS1 rearranged non-small cell lung cancer (NSCLC) in a middle-aged non-smoker. The patient presented with metastatic NSCLC and extensive disease in multiple organs. He was treated with crizotinib 250...
Na minha lista:
| Udgivet i: | BMJ Case Rep |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5093785/ https://ncbi.nlm.nih.gov/pubmed/27797842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-217322 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|